Delayed prolonged drug delivery

Patent metadata

Field	Value
Publication number	US-9283192-B2
Application number	US-201113582926-A
Country	US
Kind code	B2
Filing date	Mar 4, 2011
Priority date	Mar 5, 2010
Publication date	Mar 15, 2016
Grant date	Mar 15, 2016

Abstract

In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released in a prolonged manner at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released whilst a subject is sleeping, shortly before waking and continues to administer the drug during the early waking hours. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for a delayed, followed by a prolonged release of drug.

First claim

The invention claimed is:

1. A press-coated tablet formulation for a delayed, followed by a prolonged release of an active agent, the press-coated tablet formulation comprising:
(a) a core comprising the active agent together with a wax and optionally one or more fillers; and
(b) a delayed release layer surrounding the core and comprising a wax and a low substituted hydroxypropyl cellulose in a ratio of 20:80 to 50:50 w/w; wherein the delayed release layer delays release of the active agent within the core for between 2-8 hours after administration of the press-coated tablet formulation to a subject and thereafter a prolonged release of the active agent from the core occurs, such that the active agent in the core is continuously released over a period of 2 up to 8 hours and wherein the low substituted hydroxypropyl cellulose is micronised with a mean particle diameter of 20 μm and has a molecular weight of 115,000 and a hydroxypropyl content of 8%.

2. The press-coated tablet formulation according to claim 1 , further comprising:
(c) a top-coating layer comprising an active agent together with one or more excipients, wherein at least 70% of the active agent in the top-coating layer is released within 5-45 minutes following administration to the subject of the press-coated tablet formulation.

3. The press-coated tablet formulation according to claim 2 further comprising an amount of an active agent, which is the same or different to the active agent in the core and/or top-coating layer, in the delayed release layer.

4. The press-coated tablet formulation according to claim 2 wherein at least 80% of the active agent in the top-coating layer is released within 5-45 minutes following administration to the subject of the press-coated tablet.

5. The press-coated tablet formulation according to claim 4 , wherein at least 80% of the active agent in the top-coating layer is released within 10-30 minutes following administration to the subject of the press-coated tablet formulation.

6. The press-coated tablet formulation according to claim 2 , wherein at least 90% of the active agent in the top-coating layer is released within 5-45 minutes following administration to the subject of the press-coated tablet formation.

7. The press-coated tablet formulation according to claim 6 , wherein at least 90% of the active agent in the top-coating layer is released within 10-30 minutes following administration to the subject of the press-coated tablet formulation.

8. The press-coated tablet formulation according to claim 2 , wherein at least 70% of the active agent in the top-coating layer is released within 10-30 minutes following administration to the subject of the press-coated tablet formulation.

9. The press-coated tablet formulation according to claim 1 wherein the active agent is designed to treat cardiovascular conditions selected from the group consisting of hypertension, angina pectoris and cardiac arrhythmia.

10. The press-coated tablet formulation according to claim 9 wherein the press-coated tablet formulation comprises verapamil.

11. The press-coated tablet formulation according to claim 1 wherein the wax for use in the core and the delayed release layer is independently selected from beeswax, carnuba wax, microcrystalline wax, hydrogenated castor oil and a glyceryl ester.

12. The press-coated tablet formulation according to claim 11 wherein the glyceryl ester is glycerol behenate.

13. The press-coated tablet formulation according to claim 11 wherein the wax in the core and the delayed release layer is the same or different.

14. The press-coated tablet formulation according to claim 1 wherein the wax in the delayed release layer and the low substituted hydroxypropyl cellulose are present in a ratio of 25:75 to 40:60 w/w.

15. The press-coated tablet formulation according to claim 1 further comprising one or more pH-dependent, pH-independent, aesthetic or functional coatings.

16. The press-coated tablet formulation according to claim 15 wherein the coating is a gastro-resistant coating.

17. The press-coated tablet formulation according to claim 1 wherein the active agent in the core is continuously released over a period of 3-6 hours.

18. The press-coated tablet formulation according to claim 1 wherein less than 10% of the active agent within the core is released for between 2-8 hours after administration of the press-coated tablet formulation tablet to the subject.

19. The press-coated tablet formulation according to claim 18 wherein less than 5% of the active agent within the core is released for between 2-8 hours after administration of the press-coated tablet formulation tablet to the subject.

20. The press-coated tablet formulation according to claim 18 wherein less than 1% of the active agent within the core is released for between 2-8 hours after administration of the press-coated tablet formulation tablet to the subject.

21. The press-coated tablet formulation according to claim 1 , comprising one or more of the following active agents:
Antacids selected from the group consisting of aluminium hydroxide, magnesium carbonate, magnesium trisilicate, hydrotalcite, and simeticonealginates;
Antispasmodics selected from the group consisting of atropine sulphate, dicycloverine hydrochloride, hyoscine butylbromine, propantheline bromide, alverine citrate, and mebeverine hydrochloride;
Motility stimulants selected from the group consisting of metoclorpramide and domperidone;
H2-Receptor antagonists selected from the group consisting of Cimetidine, famotidinenizatidine, and ranitidine;
Antimuscarinics;
Chelates selected from the group consisting of Tripotassium dicitratbismuthate and sucralfate;
Prostaglandin analogues;
Aminosalicylates selected from the group consisting of balsazide sodium, mesalazine, olsalazine, and sulphasalazine;
Corticosteroids selected from the group consisting of beclometasone dipropionate, budenoside, hydrocortisone, and prednisolone;
Affecting immune response selected from the group consisting of ciclosporin, mercaptopurine, methotrexate, adalimumab, and infliximab;
Stimulant laxatives selected from the group consisting of bisacodyl, dantron, docusate, and sodium picosulfate;
Drugs affecting biliary composition and flow;
Bile acids sequestrants selected from the group consisting of colestyramine, Oxyphencyclimine, Camylofin, Mebeverine, Trimebutine, Rociverine, Dicycloverine, Dihexyverine, Difemerine, Piperidolate, Benzilone, Mepenzolate, Pipenzolate, Glycopyrronium, Oxyphenonium, Penthienate, Methantheline, Propantheline, Otilonium bromide, Tridihexethyl, Isopropamide, Hexocyclium, Poldine, Bevonium, Diphemanil, Tiemonium iodide, Prifinium bromide, Timepidium bromide, Fenpiverinium, Papaverine, Drotaverine, Moxaverine, 5-HT3 antagonists, 5-HT4 agonists, Fenpiprane, Diisopromine, Chlorbenzoxamine, Pinaverium, Fenoverine, Idanpramine, Proxazole, Alverine, Trepibutone, Isometheptene, Caroverine, Phloroglucinol, Silicones, Trimethyldiphenylpropylamine, Atropine, Hyoscyamine, Scopolamine, Butylscopolamine, Methylscopolamine, Methylatropine, Fentonium, Cimetropium bromide, and primarily dopamine antagonists;
Proton pump inhibitors selected from the group consisting of Omeprazole, lansoprazole, pantoprazole, esomeprazole, and rabeprazole sodium;
Opioids and opioid receptor antagonists;
Analgesics selected from the group consisting of Acetaminophen, Diclofenac, Diflunisal, Etodolac, Fenoprofen, Flurbiprofen, Ibuprofen, Indomethacin, Ketoprofen, Ketorolac, Meclofen

Assignees

• Mullen Alexander
• Stevens Howard
• Eccleston Sarah
• Univ Strathclyde

Inventors

• Mullen Alexander
• Stevens Howard
• Eccleston Sarah

Classifications

• A61P9/12

  Antihypertensives · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title